Dr Connie Diakos

  • BSc (Hons) PhD MBBS FRACP
  • Medical Oncologist
  • Spoken languages English

Overview

Medical oncology research is a passion of mine and I can now apply the knowledge I gained from research to the care of patients with cancer.

Special clinical interest in gastrointestinal, breast and gynaecological cancers

Dr Connie Diakos is a medical oncologist specialising in gastrointestinal, breast, gynaecological and neuroendocrine cancers. She holds a PhD in the mechanism of action of platinum anti-cancer drugs from the University of Sydney, and is an active translational researcher investigating the causes and consequences of inflammation in cancer in the Bill Walsh Translational Cancer Research Laboratory at the Kolling Institute of the University of Sydney.

She is a Staff Specialist at Royal North Shore Hospital and holds admitting rights to North Shore Private Hospital. She is a conjoint senior lecturer at the University of Sydney.

Research interests

Dr Diakos’ research is focused on finding markers to help guide treatment and predict disease course and treatment response. Her main focus is on bowel, breast and gynaecological cancers and encourages all of her patients to become involved in studies and trials. It’s through research that we are able to effect significant changes to patients’ lives. Dr Diakos is an active member of the cooperative trials groups AGITG, ANZGOG, BCT.

Professional memberships

MOGA, COSA, AGITG, ANZGOG, ESMO, ASCO, BCT, ENETS.

Publications and affiliations

  • Cancer-related inflammation and treatment effectiveness. C.I. Diakos, K.A. Charles, D.C. McMillan, S.J. Clarke. Lancet Oncology 2014; 15: e493-503.
  • A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis. F. Vafaee, C.I. Diakos, M.B. Kirschner, G. Reid, M. Michael, L.G. Horvath, Z.J. Cheng, Z. Kuncic, S.J. Clarke. npj Systems Biology and Applications 2018 4(1), 20.
  • The lymphocyte-to-monocyte ratio is a superior predictor of survival in comparison to established biomarkers of resectable colorectal cancer. J.C.Y. Chan, D.L. Chan, C.I. Diakos, A. Engel, N. Pavlakis, A. Gill, S.J. Clarke. Annals of Surgery 2017; 265(3), 539-546.
  • Tumour sidedness is not an independent prognostic marker of colorectal cancer patients undergoing curative resection: A retrospective cohort study. J.C.Y. Chan, C.I. Diakos, D.L. Chan, A. Engel, A. Gill, S.J. Clarke; PLOS One; 2019 14(6), e0218207.
  • A longitudinal investigation of inflammatory markers in colorectal cancer patients perioperatively demonstrates benefit in serial re-measurement. J.C.Y. Chan, C.I. Diakos, D.L. Chan, A. Engel, N. Pavlakis, A. Gill, S.J. Clarke. Annals of Surgery 2018; 267(6): 1119-1125.